Genomic Health Announces Positive Preliminary Results Of Oncotype DX® Study In DCIS B

[News]

Genomic Health, Inc. (Nasdaq: GHDX) announced positive preliminary results from a study of Oncotype DX® in patients with DCIS (ductal carcinoma in situ of the breast) conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative group supported by the National Cancer Institute...

More... (http://www.medicalnewstoday.com/releases/226374.php)